Genes with roles in the IL‐2 pathway have led to many of most important biological insights into T1D biology, leading to clinical trials of low‐dose IL‐2, which upregulates the activity of regulatory T cells, for T1D therapy in children (Marcovecchio et al. 2020; Todd et al. 2016). The gene discussed is IL2; the disease is type 1 diabetes mellitus.